Paolo Fornengo
Overview
Explore the profile of Paolo Fornengo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fornengo P, Mattivi S, Rinaudo E, Lepore F, Iemmolo I, Bracciama V, et al.
Curr Med Res Opin
. 2025 Feb;
41(2):209-217.
PMID: 39931866
Introduction: Familial hypercholesterolaemia (FH) is a genetic disorder associated with high cholesterol levels and an increased risk of premature cardiovascular events. Rare forms, such as semi-dominant bi-allelic mutations, pose diagnostic...
2.
Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F, et al.
Biomolecules
. 2025 Jan;
15(1).
PMID: 39858515
Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a...
3.
Bima C, Parasiliti-Caprino M, Rumbolo F, Ponzetto F, Gesmundo I, Nonnato A, et al.
Nutr Metab Cardiovasc Dis
. 2024 Apr;
34(7):1639-1648.
PMID: 38570234
Background And Aim: Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been proposed as mediators of endothelial dysfunction. In this study, we aimed to investigate the diagnostic and prognostic role...
4.
Porta M, Chiesa M, Fornengo P, Franceschini M, Tricarico L, Mazzeo A, et al.
Diabet Med
. 2021 May;
38(10):e14609.
PMID: 34043833
No abstract available.
5.
Trento M, Franceschini M, Fornengo P, Tricarico L, Mazzeo A, Bertello S, et al.
Endocrine
. 2021 Mar;
73(2):472-475.
PMID: 33768444
No abstract available.
6.
Trento M, Fornengo P, Amione C, Salassa M, Barutta F, Gruden G, et al.
Nutr Metab Cardiovasc Dis
. 2020 Aug;
30(11):1973-1979.
PMID: 32811740
Background And Aims: Diabetes is a suitable model to evaluate intervention programmes aimed at chronic diseases, because of its well-defined and measurable process and outcome indicators. In this study, we...
7.
Felicetti F, Sofia Cento A, Fornengo P, Cassader M, Mastrocola R, DAscenzo F, et al.
Pediatr Blood Cancer
. 2019 Dec;
67(3):e28106.
PMID: 31820553
Background: Among survivors of pediatric acute lymphoblastic leukemia (ALL), those who received hematopoietic stem cell transplantation (HSCT) conditioned with total-body irradiation (TBI) show the highest risk of late complications, including...
8.
Trento M, Charrier L, Cavallo F, Bertello S, Oleandri S, Donati M, et al.
Acta Diabetol
. 2019 Jul;
56(11):1209-1216.
PMID: 31313005
Aims: Diabetic retinopathy remains asymptomatic until its late stages but remains a leading cause of vision impairment and blindness. We studied quality of life and the ability to deal with...
9.
Fadini G, Frison V, Simioni N, Lapolla A, Gatti A, Bossi A, et al.
J Am Heart Assoc
. 2019 Jul;
8(14):e012244.
PMID: 31269877
Background Evidence accumulated that some glucose-lowering medications protect against cardiovascular events ( CVEs ) in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. The present study evaluated...
10.
Porta M, Amione C, Barutta F, Fornengo P, Merlo S, Gruden G, et al.
Endocrine
. 2018 Sep;
63(2):284-292.
PMID: 30173329
Purpose: We examined the expression of a panel of epigenetic enzymes catalyzing histone tails post-transcriptional modifications, together with effectors of metabolic and inflammatory alterations, in type 2 diabetes. Methods: Cross-sectional,...